A β-amyloid and Tau Imaging in Dementia

The introduction of in vivo imaging of A β-amyloid (Αβ) pathology more than a decade ago, transformed the assessment of Alzheimer disease (AD) allowing the evaluation of Aβ deposition over time by providing highly accurate, reliable, and reproducible quantitative statements of regional or global Aβ burden in the brain to the extent th at Aβ imaging has already been approved for clinical use and is being used for both patient recruitment and outcome measure in current anti-Αβ therapeutic trials. Aβ imaging studies have deepened our insight into Aβ deposition, showing that Aβ accumulation is a slow and protracted process exte nding for more than two decades before the onset of the clinical phenotype.

Source: Seminars in Nuclear Medicine - October 12, 2016 Category: Nuclear Medicine Authors: Victor L. Villemagne, Vincent Dor é, Pierrick Bourgeat, Samantha C. Burnham, Simon Laws, Olivier Salvado, Colin L. Masters, Christopher C. Rowe Source Type: research